Umberto Basso

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations

Lore Decoster, Katrien Van Puyvelde, Supriya G. Mohile et al. · Annals of Oncology · 2014 · 747 citations · Full text

Siog Recommendations, Geriatric Oncology, Aging +12

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo et al. · The Lancet Oncology · 2017 · 473 citations

Tumor Biology, Surgical Oncology, Malignant Disease +10

Treatment of Estrogen Receptor-Positive Breast Cancer

Franco Lumachi, Antonella Brunello, Marco Maruzzo et al. · Current Medicinal Chemistry · 2013 · 291 citations

Breast Oncology, Medicine, Pharmacology +12

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Padmanee Sharma, Arlene O. Siefker‐Radtke, Filippo de Braud et al. · Journal of Clinical Oncology · 2019 · 242 citations · Full text